ALTIMMUNE, INC.

ALT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-88.1M $-95.1M $-88.4M $-84.7M $-97.1M $-49.0M $-20.5M $-39.2M
Depreciation & Amortization $-205.0K $551.3K $428.9K $387.3K
Depreciation $112.0K $238.0K $477.0K $493.0K $400.0K $300.0K $239.8K $218.7K
Amortization
Stock-Based Compensation $16.1M $14.4M $10.6M $8.1M $5.5M $2.6M $1.3M $773.2K
Net Cash from Operating Activities $-67.5M $-79.8M $-75.8M $-62.6M $-78.2M $-34.3M $-9.6M $-9.4M
Investing Activities
Capital Expenditures $11.0K $47.0K $126.0K $12.1M $204.0K $1.2K $975.4K
Business Acquisitions
Net Cash from Investing Activities $-132.5M $-28.4M $13.7M $-73.4M $87.5M $-72.2M $-28.3M $-1.0M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $206.8M $10.0M $86.1M $56.8M $65.1M $213.5M $12.5M $32.5M
Net Change in Cash $6.8M $-98.2M $24.0M $-79.2M $74.4M $107.0M $-25.4M $22.0M
Free Cash Flow $-67.5M $-75.9M $-62.7M $-90.4M $-34.5M $-9.6M $-10.4M
← Newer Page 1 of 2 Older →